Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CDK4/6 inhibitor-induced liver injury: Clinical phenotypes and role of corticosteroid treatment

16 Apr 2024

Abstract excerpt

Background & Aims: Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors are the cornerstone of systemic therapy for patients with hormone receptor-positive, HER2-negative (HR+/HER2-) metastatic breast cancer. In the various therapeutic studies with CDK4/6 inhibitors, elevations in liver tests were more frequent than in the control groups. The mechanism of CDK4/6 inhibitor-induced liver toxicity is not well understood;...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Advanced Breast Cancer Therapies
Share to Cancer-related cognitive impairment studies
Share to HER2/EGFR in Cancer Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38961854
DOI: 10.1016/j.jhepr.2024.101098

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CDK4/6 inhibitor-induced liver injury: Clinical phenotypes and role of corticosteroid treatmentPMID 38961854Read ↗

Biological specificity of CDK4/6 inhibitors: dose response relationship,in vivosignaling, and composite response signatureSemantic proximity Read ↗

Adverse Event Profiles of CDK4/6 inhibitors: A pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) databaseSemantic proximity Read ↗

Hepatic Failure Associated with Immune Checkpoint Inhibitors: A Real-world Study from the Food and Drug Administration Adverse Event Reporting System (FAERS) DatabaseSemantic proximity Read ↗

CDK4/6 Inhibitors in Breast Cancer Treatment: Potential Interactions with Drug, Gene, and Pathophysiological ConditionsSemantic proximity Read ↗

Predictors of ribociclib-mediated antitumour effects in native and sorafenib-resistant human hepatocellular carcinoma cellsSemantic proximity Read ↗

Phenotyping Hepatic Immune-Related Adverse Events in the Setting of Immune Checkpoint Inhibitor Therapy.Semantic proximity Read ↗

Coumarin-induced Hepatotoxicity: A Narrative ReviewSemantic proximity Read ↗

Severe and prolonged cyclophosphamide-induced hepatotoxicity in a breast cancer patient carrying a CYP2B6*7 variant.Semantic proximity Read ↗

Infliximab-induced liver injury: Clinical phenotypes, autoimmunity and the role of corticosteroid treatment.Semantic proximity Read ↗

Efficient inhibition of cell proliferation and promotion of apoptosis requires continuous treatment with abemaciclibSemantic proximity Read ↗

Successful treatment by on-demand glecaprevir and pibrentasvir for hepatitis C flare during R-CHOP in patients with diffuse large B-cell lymphoma: a case report.Semantic proximity Read ↗

Targeted but Troubling: CYP450 Inhibition by Kinase and PARP Inhibitors and Its Clinical ImplicationsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.